Anixa Biosciences, Inc. (ANIX) |
|
4.08 -0.4 (-8.93%)
|
03-17 16:00 |
|
Open: |
4.48 |
Pre. Close: |
4.48 |
|
High:
|
4.64 |
Low:
|
4.08 |
|
Volume:
|
155,831 |
Market Cap:
|
126(M) |
|
|
|
Technical analysis |
as of: 2023-03-20 8:44:04 AM |
|
Overall:
|
  |
| Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected. |
| Target: |
Six months: 5.37 One year: 5.96 |
| Support: |
Support1: 3.77 Support2: 3.14 |
| Resistance: |
Resistance1: 4.6 Resistance2: 5.11 |
| Pivot: |
4.53  |
| Moving Average: |
MA(5): 4.25 MA(20): 4.4
MA(100): 4.58 MA(250): 4.04 |
| MACD: |
MACD(12,26): -0.1 Signal(9): 0 |
| Stochastic oscillator: |
%K(14,3): 32.9 %D(3): 36 |
| RSI: |
RSI(14): 44 |
| 52-week: |
High: 6.25 Low: 2.5 |
| Average Vol(K): |
3-Month: 53 (K) 10-Days: 82 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ ANIX ] has closed above bottom band by 14.3%. Bollinger Bands are 25.9% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
4.65 - 4.67 |
4.67 - 4.69 |
|
Low:
|
4.03 - 4.05 |
4.05 - 4.07 |
|
Close:
|
4.05 - 4.08 |
4.08 - 4.11 |
|
Company Description |
|
Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell technology, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer; and the discovery and development of anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain protein functions of the virus. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. It has a collaboration agreement with MolGenie GmbH to discover and develop anti-viral drug candidates against COVID-19. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California. |
Headline News |
Mon, 13 Mar 2023
Anixa Biosciences Announces No Accounts at Silicon Valley Bank ... - Investing.com India
Mon, 13 Mar 2023
Anixa Biosciences Reassures Shareholders It Has No Accounts at ... - PR Newswire
Thu, 02 Mar 2023
Anixa Biosciences to Provide Corporate Update at its 2023 Annual ... - PR Newswire
Thu, 02 Mar 2023
Anixa Biosciences, Inc.'s (NASDAQ:ANIX) Profit Outlook - Simply Wall St
Tue, 21 Feb 2023
Anixa Biosciences Announces Formation of Breast Cancer Clinical ... - Yahoo Finance
Thu, 08 Dec 2022
Anixa Biosciences Announces Maximum Tolerated Dose Reached ... - PR Newswire
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Neutral |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
31 (M) |
| Shares Float |
0 (M) |
|
% Held by Insiders
|
4.5 (%) |
|
% Held by Institutions
|
11.8 (%) |
|
Shares Short
|
574 (K) |
|
Shares Short P.Month
|
587 (K) |
Stock Financials |
|
EPS
|
-0.42 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0.93 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
0 |
|
Return on Equity (ttm)
|
0 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
0 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
0 (M) |
Stock Valuations |
|
PE Ratio
|
-9.72 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
4.34 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
0 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
